Why the study?
Anticancer treatments increasingly cause side effects such as cardiotoxicity, and docetaxel cardiotoxicity presenting as heart failure is rarely reported in the literature.
Does docetaxel cause cardiotoxicity in patients with prostate cancer?
Does docetaxel cause cardiotoxicity in patients with prostate cancer?
Docetaxel can cause rare but significant cardiotoxicity presenting as heart failure, suggesting a potential need for echocardiographic monitoring in patients receiving taxanes.
May warrant cardiac monitoring with docetaxel in prostate cancer; leaves open incidence and risk stratification.
Despite the development of anti-cancer treatments, cancers remain among the most common causes of morbidity and mortality. The prognosis depends on the natural evolution of the disease in the first instance, but also on the increasingly frequent side effects of anticancer treatments. Cardio oncology is an emerging sub-specialization in its own right that deals with these complications. We report the case of an 80-year-old patient with prostate cancer who received 8 courses of docetaxel and developed left ventricular dysfunction related to docetaxel cardiotoxicity. This case is among the few in the literature elucidating docetaxel cardiotoxicity in the form of heart failure, which should prompt consideration of echocardiographic monitoring in patients receiving taxanes.
No takes yet. Share an insight, caveat, or question.
A 2023 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: